Table 3. Respondents’ perceptions towards pharmacogenetics and its implications (n = 617).
| Responses the perception items | Pharmacists (n = 238) Frequency (%) |
Physicians (n = 379) Frequency (%) |
Total (n = 617) Frequency (%) |
P value |
|---|---|---|---|---|
| 1.Pharmacogenetics is relevant to my current clinical practice. | ||||
| Agree | 164 (69.0) | 240 (63.3) | 404 (65.5) | 0.027* |
| Neutral | 55 (23.0) | 121 (32.0) | 176 (28.5) | |
| Disagree | 19 (8.0) | 18 (4.7) | (6.0) | |
| 2. Pharmacists should be required to have some knowledge of pharmacogenetics. | ||||
| Agree | 214 (90.0) | 326 (86.0) | 540 (87.5) | 0.303 |
| Neutral | 19 (8.0) | 45 (12.0) | 64 (10.4) | |
| Disagree | 5 (2.0) | 8 (2.0) | 2.1) | |
| 3. Pharmacogenetic testing should be applied into my clinical practice. | ||||
| Agree | 180 (75.6) | 230 (60.7) | 410 (66.5) | <0.001* |
| Neutral | 50 (21.0) | 137 (36.1) | 187 (30.3) | |
| Disagree | 8 (3.4) | 12 (3.2) | 3.2) | |
| 4. Pharmacists should be asked by healthcare professionals for recommendations on appropriate use of pharmacogenetic testing. | ||||
| Agree | 162 (68.1) | 259 (68.3) | 421 (68.2) | 0.923 |
| Neutral | 63 (26.5) | 102 (27.0) | 165 (26.7) | |
| Disagree | 13 (5.5) | 18 (4.7) | 5) | |
| 5. I should be able to provide information on appropriate use of pharmacogenetic testing. | ||||
| Agree | 177 (74.4) | 224 (59.1) | 401 (65.0) | <0.001* |
| Neutral | 43 (18.1) | 137 (36.1) | 180 (29.2) | |
| Disagree | (7.6) | 18 (4.7) | (5.8) | |
| 6. Pharmacogenetics will improve our ability to more effectively control drug therapy expenditures. | ||||
| Agree | 184 (77.3) | 225 (59.4) | 409 (66.3) | <0.001* |
| Neutral | 40 (16.8) | 131 (34.6) | 171 (27.7) | |
| Disagree | 14 (5.9) | 23 (6.1) | 37 (6.0) | |
*Significant difference between physicians and pharmacists using Chi-square test